Growth dynamics of transversal body dimensions and proportions, with related clinical determinants in children with X-linked hypophosphatemia treated with phosphate supplements and active vitamin D.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this observational study publication.

Children with X-linked hypophosphatemia (XLH) present with rickets, leg deformities, and growth failure.

Bone stability depends on balanced bone growth in both length and width.

Who Took Part

The abstract describes 109 patients taking part.

The age groups tagged for this paper are young children, children and teenagers, both men and women.

Six major transverse body dimensions of the trunk and extremities, and the frame index (FI), i.e., ratio between bicondylar humerus diameter and height, were measured annually along with clinical characteristics in 109 pediatric patients with XLH, all on supplementation therapy, participating in a prospective multicenter observational study conducted since 1998.

How the Study Was Run

In design terms this was a multicenter study.

More than one site took part, so the patients came from several places.

Associations between anthropometric and clinical parameters were investigated using linear mixed-effects models.

What Was Measured

Topics PubMed links to this paper include Familial Hypophosphatemic Rickets, Vitamin D, Phosphates, Dietary Supplements and Bone Development.

Author keywords: Alkaline phosphatase, Body disproportion, Frame index, Transversal body dimension and XLH.

What This Means in Plain Language

The paper is a multicenter study of Vitamin D, K2, Magnesium and Zinc in 109 patients.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Pediatric nephrology (Berlin, Germany)), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.